Circumvent Pharmaceuticals
Portland, Oregon, United StatesSee on the mapFounded 2017
- Seed
Circumvent Pharmaceuticals develops precision medicines for neurodegenerative diseases, beginning with Batten Disease, with an initial focus on CLN1. The company applies insights into brain-cell dysfunction and the palmitoylome to pursue treatments for rare and common neurological disorders.
- RaisedTotal raised
- $15.4M
- Dec 2020Latest priced round, Dec 2020
- Seed
- Investors
- 4
- Founded
- 2017
- Employees
- 1–10
reccy insights
The available dated milestones are concentrated between 2019 and 2021, so there is limited basis for describing newer company developments. Circumvent’s listed financing history begins with a $150,000 pre-seed round led by Y Combinator on Mar 18, 2019, followed by a $4.092 million seed round on Dec 9, 2020. In 2021, the company’s funding entries include a $25,000 Regulation Crowdfunding round dated Jul 12, 2021 and grant activity. Two grants are listed on Nov 1, 2021, for $495,000 and $3.69 million; another grant entry, attributed to HHS, is dated Sep 20, 2021 for $6,931,425. These grant figures do not reconcile cleanly with the stated total funding, so they should not be treated as a verified combined grant total. The company’s research focus is precision medicine for neurodegenerative disease, beginning with CLN1 Batten disease. As of Nov 20, 2026, the listed milestones are historical rather than recent.
Written by reccy's AI from company sites, press and funding records · updated Nov 2026
What makes Circumvent Pharmaceuticals distinct
- 01Initially focuses on CLN1 Batten disease, a severe rare disease.
- 02Uses Batten disease research to investigate brain-cell dysfunction with relevance to other neurological conditions.
- 03Studies the palmitoylome and explores therapeutic strategies to modulate it.
- 04Prioritizes diseases with predictive animal models and a clear clinical development path.
- 05Engages patients, caregivers, and patient advocacy organizations in research and development.
Technology & products
- CLN1 Batten disease program
An initial precision-medicine drug-development program focused on CLN1 Batten disease.
- Palmitoylome characterization and therapeutic modulation
- Research into the synaptome and its effects on synaptic function
- Precision-medicine development for CLN1 Batten disease and related neurological disorders
Funding
- GrantNov 2021$495K
- GrantNov 2021$3.7M
- GrantSep 2021$6.9MLed by HHS
Investors2
About Circumvent Pharmaceuticals
- Products
- CLN1 Batten disease program
- Leadership
- Andrew LimDevin WileySamy Hamdouche
- Focus areas
- Neurotechnology, biotechnology, pharmaceuticals, neurodegenerative disease, rare disease, batten disease, precision medicine, drug development
- Headquarters
- Portland, Oregon, United States
- Founded
- 2017
- Employees
- 1–10
- Status
- Active · private